Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt

Oncology

QPS Study Shows Estetrol Promising for Prostate Cancer Treatment

Clinical Trials /

An investigation into the efficacy and safety of Estetrol (E4) for potential use in the treatment of advanced prostate cancer demonstrated decreased testosterone levels along with acceptable safety parameters. These results suggest that E4 may be suitable for standalone or combination treatment with androgen deprivation therapy (ADT). QPS Netherlands performed the Phase II randomized, double-blind, […]

QPS Study Shows Estetrol Promising for Prostate Cancer Treatment Read More »

DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD

Therapeutic Areas /

Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD). Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Cabozantinib is currently approved

DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD Read More »

Time is of the essence in Drug Development.

Contact the QPS Business Development Team Today!

Your link to a rewarding career.

Join the QPS team and be part of our growing organization.

Submit Your Resume

About qps

Preclinical Services

Clinical Services

Resources

Headquarters Location

Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711

Connect with us

Linkedin-in Youtube Facebook-f Instagram
download-ios
download-google
qps-assay-finder-black
Copyright © 2024 · QPS Holdings. All Rights Reserved
Scroll to Top